Prognostic Significance of the ESTRO/EORTC Classification of Oligometastatic Disease for Colorectal Cancer Patients With Uncommon Metastases Treated With Definitive Radiotherapy. [PDF]
Ke TW +11 more
europepmc +1 more source
Background Immune checkpoint inhibitors (ICIs) have become the recommended first-line treatment for advanced non-small cell lung cancer (NSCLC) without driver gene mutations. However, data on the failure patterns of first-line ICIs monotherapy is limited,
Qing Zhou +5 more
core +1 more source
Case Report: Four-year durable remission, cerebral oligoprogression, and femoral head necrosis following severe recurrent immune checkpoint inhibitor-related pneumonitis in a patient with stage IV lung adenocarcinoma. [PDF]
Xue Y, Xu A, Tong X, Yin X, Wei L.
europepmc +1 more source
Metastatic Malignant Mesothelioma of the Tunica Vaginalis Testis Treated With Sequential Immunotherapy, Chemotherapy, and Radiotherapy With Prolonged Disease Stabilisation: A Case Report. [PDF]
Mathiyalagan N +7 more
europepmc +1 more source
Continuation of Tarlatamab With Concomitant Radiotherapy for Oligoprogression in Extensive-Stage Small-Cell Lung Cancer: A Report of Two Cases. [PDF]
Masui R, Omori S, Ueno T, Komiya K.
europepmc +1 more source
What is oligoprogression?—a narrative review
Lucas Uhl +7 more
openaire +1 more source
Continuation of First-Line Systemic Therapy with Progression-Directed Radiotherapy in Patients with Oligoprogressive Hepatocellular Carcinoma: A Multicenter, Single-Arm, Phase II Trial. [PDF]
Shi F +12 more
europepmc +1 more source
Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change. [PDF]
Günaltılı M +13 more
europepmc +1 more source
The heterogeneity in oligoprogression and stereotactic body radiation therapy
Hayashi, Takafumi, Takigawa, Nagio
openaire +2 more sources
Consensus statements on the definition, diagnosis, and management of oligoprogressive disease: results of an expert survey of Kazakhstan Cancer Society. [PDF]
Kaidarova D +9 more
europepmc +1 more source

